OIM
YMAB

Oracle Investment Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Oracle Investment Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-315,642
Closed -$9.01M – 50
2021
Q3 		$9.01M Buy
315,642
+15,000
+5% +$473K 1.12% 14
2021
Q2 		$10.2M Sell
300,642
-80,000
-21% -$2.57M 1.4% 14
2021
Q1 		$11.5M Buy
380,642
+254,300
+201% +$10.4M 1.72% 12
2020
Q4 		$6.25M Buy
126,342
+101,130
+401% +$4.68M 0.78% 12
2020
Q3 		$968K Hold
25,212
– – 0.13% 15
2020
Q2 		$1.09M Hold
25,212
– – 0.14% 15
2020
Q1 		$658K Buy
+25,212
New +$732K 0.2% 16

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Oracle Investment Management's YMAB Position: Q4 2021 in Review

Oracle Investment Management sold out of Y-mAbs Therapeutics (YMAB) in Q4 2021, closing a stake of 315,642 shares — an estimated $9.01M sold.

Oracle Investment Management first reported a position in YMAB in Q1 2020 and held it in 7 quarters. The position peaked at $11.5M in Q1 2021. 97 funds tracked by Wall St. Rank hold YMAB as of Q4 2021.

  • Oracle Investment Management reported no remaining Y-mAbs Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Oracle Investment Management sold 315,642 Y-mAbs Therapeutics shares in Q4 2021, an estimated $9.01M.
  • Oracle Investment Management first reported a position in Y-mAbs Therapeutics in Q1 2020 and held it in 7 quarters.
  • Oracle Investment Management's Y-mAbs Therapeutics position peaked at $11.5M in Q1 2021.
  • 97 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2021.

Based on Oracle Investment Management's 13F filing for Q4 2021, filed 14 Feb 2022.